DrugId:  1
1. Name:  Tocilizumab
2. Groups:  Approved
3. Description:  Tocilizumab is a recombinant, humanized, anti-human interleukin 6 (IL-6) receptor monoclonal antibody that achieves a significant therapeutic response rate. The light chain is made up of 214 amino acids. The heavy chain is made up of 448 amino acids. The four polypeptide chains are linked intra- and inter-molecularly by disulfide bonds. FDA approved on January 8, 2010. Tocilizumab (injection) was further approved by the FDA for the treatment of adults with giant cell arteritis, an inflammation of the blood vessels (vasculitis) in May, 2017. In a double-blind, placebo-controlled study, the patients achieved sustained remission from Week 12 through Week 52, which was associated with significant improvements in symptoms of giant cell arteritis, normalization of inflammatory laboratory tests and tapering the use of corticosteroids [2].
4. Indication:  Indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
DrugId:  2
1. Name:  Interferon Alfa-2a, Recombinant
2. Groups:  Approved, Investigational
3. Description:  Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
4. Indication:  For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.
DrugId:  3
1. Name:  Interleukin-10
2. Groups:  Investigational
3. Description:  Interleukin-10 has been used in trials studying the prevention and treatment of Vasculitis, Pancreatitis, Bile Duct Diseases, Pancreatic Diseases, and Gallbladder Diseases, among others.
4. Indication:  Not Available
DrugId:  4
1. Name:  Pristinamycin
2. Groups:  Experimental, Investigational
3. Description:  Not Available
4. Indication:  Not Available
DrugId:  5
1. Name:  Sitafloxacin
2. Groups:  Experimental, Investigational
3. Description:  Not Available
4. Indication:  Not Available
DrugId:  6
1. Name:  Rontalizumab
2. Groups:  Investigational
3. Description:  Rontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus.
4. Indication:  Not Available
DrugId:  7
1. Name:  Blisibimod
2. Groups:  Investigational
3. Description:  Blisibimod has been used in trials studying the treatment of IgA Nephropathy, Microscopic Polyangiitis, Systemic Lupus Erythematosus, and Granulomatosis With Polyangiitis.
4. Indication:  Not Available
DrugId:  8
1. Name:  PSN357
2. Groups:  Investigational
3. Description:  PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
4. Indication:  Investigated for use/treatment in diabetes mellitus type 2.
DrugId:  9
1. Name:  Iclaprim
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in bacterial infection, skin infections/disorders, obesity, liver disease, kidney disease, and pneumonia.
DrugId:  10
1. Name:  Tabalumab
2. Groups:  Investigational
3. Description:  Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
4. Indication:  Not Available
DrugId:  11
1. Name:  Ruplizumab
2. Groups:  Investigational
3. Description:  Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.
4. Indication:  Investigated for use/treatment in thrombocytopenia, systemic lupus erythematosus, transplant (rejection), blood (blood forming organ disorders, unspecified), and multiple sclerosis.
DrugId:  12
1. Name:  Atacicept
2. Groups:  Investigational
3. Description:  Atacicept is a recombinant fusion protein combined with the extracellular ligand binding portion of TACI.
4. Indication:  Investigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid).
DrugId:  13
1. Name:  AT1022
2. Groups:  Investigational
3. Description:  AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain.AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect.
4. Indication:  Investigated for use/treatment in pain (acute or chronic).
DrugId:  14
1. Name:  Forigerimod
2. Groups:  Investigational
3. Description:  Forigerimod is under investigation for the treatment of Lupus Erythematosus, Systemic.
4. Indication:  Not Available
DrugId:  15
1. Name:  Fresolimumab
2. Groups:  Investigational
3. Description:  Fresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis.
4. Indication:  Not Available
DrugId:  16
1. Name:  Cortivazol
2. Groups:  Investigational
3. Description:  Cortivazol is under investigation in clinical trial NCT00804895 (Cluster Headache Cortivazol Injection (CHCI)).
4. Indication:  Not Available
DrugId:  17
1. Name:  Iodine povacrylex
2. Groups:  Approved
3. Description:  Iodine povacrylex (DuraPrep) is a surgical solution, film-forming iodophor complex that provides fast acting, persistent, broad-spectrum antimicrobial activity. DuraPrep solution is indicated for use as a patient preoperative skin preparation, for the preparation of the skin prior to surgery and to help reduce bacteriathat can potentially cause skin infection.It is broad spectrum antispectic and can provide almost 99.9% antispectic conditions.It is intended for local use only. Prolonged skin exposure could cause skin defatting manifested by the following signs/symptoms; localized redness, itching, drying and cracking of skin.
4. Indication:  Antispetic and germicidal agent. It is indicated for use as a patient preoperative skin preparation, for the preparation of the skin prior to surgery and to help reduce bacteria that can potentially cause skin infection.
DrugId:  18
1. Name:  Cloprednol
2. Groups:  Experimental
3. Description:  Cloprednol is a synthetic glucocorticoid that has been investigated for use in the treatment of asthma. [1, 2]
4. Indication:  Not Available
DrugId:  19
1. Name:  Motavizumab
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in viral infection and pediatric indications.
DrugId:  20
1. Name:  LX201
2. Groups:  Investigational
3. Description:  LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. The implant is being developed clinically for the prevention of rejection in corneal transplantation. It is being developed by Lux Biosciences, Inc.
4. Indication:  Investigated for use/treatment in eye disorders/infections and transplant (rejection).
DrugId:  21
1. Name:  Garenoxacin
2. Groups:  Investigational
3. Description:  Garenoxacin (INN) is a quinolone antibiotic undergoing regulatory review for the treatment of gram-positive and gram-negative bacterial infections. [Wikipedia]
4. Indication:  Investigated for use/treatment in bacterial infection.
DrugId:  22
1. Name:  Meprednisone
2. Groups:  Approved, Investigational
3. Description:  Not Available
4. Indication:  Not Available
DrugId:  23
1. Name:  Maribavir
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in viral infection, transplantation (organ or tissue), cytomegalovirus (CMV) retinitis, and retinal disorders (unspecified).
DrugId:  24
1. Name:  Nemonoxacin
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in bacterial infection and pneumonia.
DrugId:  25
1. Name:  Flumequine
2. Groups:  Withdrawn
3. Description:  Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.
4. Indication:  Not Available
